According to the European Commission, if a biotech company crosses two plants to create a new plant through natural means, the outcome will not be patentable, explains Jane Wainwright of Potter Clarkson in a video interview with LSIPR.
In this video, Wainwright discusses the commission’s review of the biotech directive and the implications of its opinion on plant patentability.
Potter Clarkson, Jane Wainwright, , patents, video, plant, European Commission, biotech directive
